Loading
Total declarations
Companies
▲ Purchases (2 ops.)
▼ Sales (9 ops.)
Latest filing published 21 May 2021 for Passage BIO, Inc., €25k.
Filing timeline
BuySaleRichard Steven Morris
Insider track record
Disclosed buys
2
Disclosed sells
9
T+90 hit rate
0%
T+90 mean return
-10.2%
Across 1 buy signal with a settled T+90 return. Return basis: close on the day after publication.
Signal history
No signal scores available.
Richard Steven Morris: trading record in brief
Richard Steven Morris (finance chief) discloses dealings in 3 companies, chiefly Viropharma Inc, Passage BIO, Inc. and Vitae Pharmaceuticals, Inc. In total, 20 filings cover trades dated from 11 September 2008 to 21 May 2021.
Market trades split into 2 purchases (€31k) and 9 sales (€399k). Sales outweigh purchases by €368k. Buying on the open market means paying the going price with one's own funds, a different act from receiving shares as pay. Besides market trades, the filings include 1 share grant and 7 option exercises. Since January 2021: 1 purchase and no sales on the market.
Most recently, on 21 May 2021, the filings show an open-market purchase worth €25k in Passage BIO, Inc. The median gap between a trade and its publication by SEC (Form 4) is 2 days. For comparison, the SEC allows two business days to file a Form 4. Sales are harder to read than purchases, since they often meet personal needs such as tax or diversification. This summary is built from SEC (Form 4) disclosures alone and does not predict where the share price will go.
Companies and markets linked to Richard Steven Morris
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
Declarations1 total
2,171 shares@ US$13.8183100.0% of flowCommon StockSEC:0001209191-21-035059:0
Canonical exit: 19 Aug 2021 (T+90)
1 of 1 declaration
